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Abstract
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are 
a subset of mesenchymal tumours that represent the most com-
mon mesenchymal neoplasms of the gastrointestinal (GI) tract 
and account for less than 1% of all gastrointestinal tumours. 
MATERIAL AND METHODS: We retrospectively evaluated 19 
patients (6 females and 13 males; median age: 61 years ± 15 
standard deviation) affected by GIST histologically documented 
after surgical intervention or biopsy. 
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes 
and was considered positive for neoplastic tissue in 10 patients 
(53%) and negative in 9 (47%), in concordance with radiologi-
cal findings. 
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and 
accurate method to restage patients affected by previously histo-
logically confirmed GIST, also in the absence of a staging study.
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Introduction
Gastrointestinal stromal tumours (GISTs) are a subset of 
mesenchymal tumours that represent the most common mesen-
chymal neoplasms of the gastrointestinal (GI) tract and account 
for less than 1% of all gastrointestinal tumours. GISTs are tyrosine 
kinase receptor (c-KIT)-expressing and many have an activating 
mutation in either KIT or platelet-derived growth factor receptor 
alpha (PDGFRa) [1, 2]. Their origin was initially attributed to Ca-
jal’s cells but it has recently been supposed that they originate 
from multipotential mesenchymal stem cells [3], which could 
explicate their resistance to chemotherapy, and which has lead 
to the introduction of imatinib mesylate therapy (a tyrosine kinase 
inhibitor for c-KIT). Their incidence is very low (approximately 
10–20 per million people, per year) with no demonstrated sig-
nificant association with ethnicity, race, geographic location, or 
occupation. The most common locations of GIST are stomach 
(50–60%), small intestine (30–40%), colon-rectum (5–10%), 
oesophagus (5%), and other less common locations outside the 
GI tract (mesentery, retroperitoneum, and omentum) but there 
have been reported cases in the pancreas, liver, gallbladder, and 
urinary bladder, and when GISTs occur outside the GI tract they 
are known as extra-gastrointestinal stromal tumours (EGISTs) 
[1, 4]. Approximately 70% of the patients are symptomatic 
complaining of nausea, vomiting, abdominal discomfort, weight 
loss or early satiety, and, in presence of large lesions (GIST vary 
greatly in size from a few millimetres to more than 30 centime-
tres), signs and symptoms related to the presence of a mass or 
bleeding due to the erosion of the GI tract lumen. Distant metas-
tases most commonly occur in GIST tumours of the peritoneum, 
omentum, mesenteric areas, and liver, and rectal GISTs frequently 
metastasize to the lungs [1]. GISTs show a variety of differentiation 
possibilities ranging from fully differentiated tumours to incom-
plete or mixed differentiation, and differential diagnosis could 
be considered for neuroendocrine tumours, fibromatosis or 
desmoid tumours, leiomyoma, schwannoma, and angiosarcoma 
[1, 5]. The diagnostic studies include several examinations, such 
as barium examination of the GI tract, computer tomography 
(CT), and angiography. Preoperative percutaneous biopsy should 
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not be used as it is associated with a significant risk of tumour 
rupture or dissemination [6], but the effective role of endoscopic 
ultra-sound guided fine needle aspiration has been pointed out in 
several studies with high reported accuracy [7]. GISTs generally 
have an unpredictable outcome due to their uncertain clinical 
behaviour, ranging from benign to frankly malignant, and the 
most significant prognostic factors seem to be size and mitotic 
count [1]. Surgical resection of the local disease, when possible, 
is the gold standard therapy in the absence of regional lymph 
node resection as it has no value since GIST rarely gives rise to 
lymph node metastases [1, 8–10]. Complete surgical resection 
is connected with 65% five-year survival [8], and when complete 
resection is not feasible, imatinib mesylate therapy is very ef-
fective for tumour treatment in advanced or metastatic disease 
(GISTs have a high risk of metastatic relapse) even if resistance 
to imatinib mesylate has been reported [3, 11]. The prognosis of 
low-risk GIST after complete surgical resection is generally good; 
instead, the prognosis of high-risk GIST is low with a high rate of 
recurrence even if, after the introduction of molecular targeted 
therapy with imatinib mesylate, a major improvement in the 
survival has been shown [12].
Aim
The aim of this study was to evaluate the feasibility, utility, and 
efficacy of 18FDG-PET/CT in restaging patients affected by GIST 
who were treated by surgery or imatinib mesylate, in the absence 
of a staging PET and comparing the results with radiological 
imaging for a validation.
Material and methods
We retrospectively evaluated 19 Patients (6 females and 
13 males; median age: 61 years ± 15 standard deviation) af-
fected by GIST histologically documented after surgical interven-
tion or biopsy and localized in the stomach in 8 patients (42%), 
in small intestine in 8 patients (42%), and in colon-rectum in 3 
(16%). The first-line treatment after diagnosis was surgery in 13 
patients (68%), surgery and imatinib mesylate in 4 patients (21%), 
and imatinib mesylate only in 2 patients (11%). All Patients un-
derwent F18-FDG-PET/CT for restaging purposes in order to 
identify possible relapse of disease (average time to restaging: 
20 months). PET/CT was performed in the fasting state for at 
least 6 hours and glucose level lower than 150 mg/dl. An FDG 
dose of 5.5 MBq/Kg was administered intravenously, and a 2D 
mode ordered-subset-expectation-maximization (OS-EM) imaging 
(with septa) was acquired 60 minutes after injection on a Discov-
ery ST PET/CT tomograph (General Electric Company — GE® 
— Milwaukee, WI, USA) with standard CT parameters (80 mA, 
120 Kv without contrast; 4 minutes per bed-PET-step of 15 cm). 
The reconstruction was performed on a 128 × 128 matrix and 
60 cm field of view. The PET images were analysed visually and 
semi-quantitatively by measuring the maximum standardized 
uptake value (SUVmax). SUV was expressed as SUV body weight 
(SUVbw — g/ml) and automatically calculated by the software 
(Volumetrix for PET/CT; Xeleris™ Functional imaging workstation; 
GE®) on the basis of following parameters: weight of the patient 
expressed in kilograms; height expressed in centimetres; tracer 
volume expressed in millilitres (ml); radioactivity at injection time 
expressed in mega-Becquerel (MBq); post injection activity in the 
vial expressed in MBq; injection time; starting time acquisition; and 
decay half-time of the radioisotope (standard 109.8 minutes for 
F18). A written consensus was obtained by all patients before every 
study. Moreover, 5 patients underwent a second F18-FDG-PET/CT 
to evaluate subsequent imatinib mesylate therapy response after 
two months. 
Results
F18-FDG-PET/CT has identified pathologic uptakes and 
has been considered positive for neoplastic tissue in 10 pa-
tients (53%) and negative in 9 (47%), considering an SUV value 
higher than 3 to be significant; pathologic uptakes were localised 
respectively in the liver in 3 patients, on the peritoneal surface in 
1, in the liver, on the peritoneal surface, and on the thoracic wall 
mass in 1 (Figure 1), in the liver and colon in 1, in the liver and on the 
peritoneal surface in 1, on the peritoneal surface and in the colon in 
1, and in the stomach in 2 (Figure 2; Figure 3). All F18-FDG-PET/CT 
results were compared with anatomic imaging; in particular, all 
patients also underwent computed tomography (CT), and 10 
underwent echography (ECHO) or magnetic resonance (MR). 
All patients negative at F18-FDG-PET/CT were also negative at 
radiologic imaging (considering negative the absence of lesions or 
the presence of unmodified, previously documented lesions with 
respect to the post-therapy radiologic studies). All patients posi-
tive at F18-FDG-PET/CT were also positive at radiologic imaging. 
Among the group of positive patients who underwent a second 
F18-FDG-PET/CT, no pathologic neoplastic uptake was revealed 
in 2 and persistent but reduced by more than 25% in 3. 
Discussion 
The role of F18-FDG-PET/CT in staging patients affected by 
GISTs is well established as these tumours have shown high glu-
cose metabolism [13–17], and a correlation between FDG uptake 
and malignant potential or prognosis has been shown [18, 19]. 
Many studies have been published on high metabolism and the 
malignant potential of GISTs; in particular Yamada et al. compared 
tumour size, mitotic index, Ki-67 labelling index (LI), and cellularity 
of the tumour tissue with the SUV of FDG in 21 patients with gastric 
GISTs after endoscopic ultrasound-guided fine needle aspiration 
(EUS-FNA) or endoscopic biopsy. They demonstrated a strong 
correlation between the SUV of FDG and EUS size and mitotic 
index, concluding that PET may be used to assess the malignancy 
of GISTs, to determine the management strategy for patients, and 
to complement the information on the biological behaviour and 
cellular proliferation of the tumours [20].
Many papers are currently available describing the role of 
F18-FDG-PET/CT in staging, follow-up, and therapy response 
monitoring, also as early as one week after starting therapy [14, 
15, 21–25]. In particular, Trent et al. used microarray technol-
ogy, real-time polymerase chain reaction (PCR) validation, and 
F18-FDG-PET imaging to study the early molecular effects of im-
atinib antitumour activity in GIST. F18-FDG-PET was performed to 
correlate radiographic findings with the effects of imatinib on gene 
expression in GIST. It was shown that imatinib appears to regulate 
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Figure 2. F18-FDG-PET/CT images of a patient with gastric relapse. Sites of pathologic uptake are highlighted (arrows). In particular, sagittal CT, 
(1-A1), PET (1-A2), and fused (1-A3) images, coronal CT, (1-B1), PET (1-B2), and fused (1-B3) images, axial CT, (1-C1), PET (1-C2), and fused 
(1-C3) images, and anterior view (1-D) of maximum intensity projection (MIP) images. 
Figure 1. F18-FDG-PET/CT images of a patient with hepatic, peritoneal, and thoracic relapse. Sites of pathologic uptake are highlighted (arrows). 
In particular, axial CT, (2-A1, 2-B1, 2-E1), PET (2-A2, 2-B2, 2-E2), and fused (2-A3, 2-B3, 2-E3) images, coronal CT (2-C1), PET (2-C2), and fused 
(2-C3) images, sagittal CT, (2-D1), PET (2-D2), and fused (2-D3) images, and anterior view (2-F) of maximum intensity projection (MIP) images. 
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numerous genes in GIST cells and tumour samples, inversely 
correlated with residual FDG uptake early in imatinib therapy [21]. 
Holdsworth et al. recently studied sixty-three patients enrolled in 
a multicentre trial evaluating imatinib mesylate therapy for advanced 
GIST, who underwent F18-FDG PET at baseline and 1 month after 
initiation of treatment to determine response to prolonged imatinib 
mesylate treatment. F18-FDG-PET has been useful in determin-
ing early response assessment and European Organisation for 
Research and Treatment of Cancer (EORTC) criteria were predic-
tive of outcome. Choi et al. have evaluated by CT and PET a total 
of 172 lesions selected by Response Evaluation Criteria in Solid 
Tumours (RECIST) in 40 patients with metastatic GISTs treated 
with imatinib before and after therapy, showing the usefulness and 
accuracy in predicting tumour progression and therapy response 
assessment [22]. Gayed et al. have studied 54 patients who under-
went F18-FDG PET and CT scans within 3 weeks before initiation 
of imatinib mesylate therapy. The performances of F18-FDG PET 
and CT have been shown to be comparable in staging GISTs before 
initiation of therapy; however, F18-FDG PET is superior to CT in 
predicting early response. Thus, F18-FDG PET has been judged 
a better guide for imatinib mesylate therapy [15]. Jager et al. evalu-
ated 16 consecutive patients who underwent FDG PET before and 
after treatment with imatinib mesylate, concluding that FDG PET 
is a valuable tool in patients with GISTs as it improves staging, ac-
curately separates responders from non-responders in the early 
phase, and is helpful during follow-up [23]. Antoch et al. compared 
the value of PET, CT, and PET/CT imaging for assessing response 
to imatinib mesylate therapy in 20 patients with histologically proven 
GIST. PET, CT, and PET/CT images were evaluated according to 
World Health Organization (WHO) Response Evaluation Criteria in 
Solid Tumours (RECIST), and European Organisation for Research 
and Treatment of Cancer (EORTC) criteria for therapy response, 
concluding that image fusion with combined PET/CT can provide 
additional information in individual cases when compared with 
side-by-side PET and CT [26]. This hypothesis has been confirmed 
in a review paper by Van den Abbeele et al. [27]. All possible ap-
plications of F18-FDG-PET/CT in GISTs evaluation include initial 
disease evaluation and early monitoring of imatinib mesylate 
therapy, evaluating malignant potential at diagnosis, residual viable 
disease assessment in post-surgery and post-imatinib therapy 
scenario, detection of acquired resistance to imatinib and disease 
recurrence, detection of synchronous and metachronous malignan-
cies, and future directions regarding PET/CT-guided personalized 
management [25]. 
Despite the small number of cases, in our study we confirmed 
the role of F18-FDG-PET/CT in GIST evaluation and in assessing 
therapy response, but mostly that is also a safe, useful, and ac-
curate method to restage patients in the absence of a staging 
study. Not infrequently, in clinical practise, the impossibility to 
have a staging study of patients, because of waiting lists, depart-
ment workloads and clinical necessities, could draw the referring 
physician to start therapy in the absence of initial evaluation. 
Undoubtedly this situation precludes the possibility of therapy 
monitoring of first line treatment, but, according to our results, the 
Figure 3. F18-FDG-PET/CT images of a patient with gastric relapse. Sites of pathologic uptake are highlighted (arrows). In particular, sagittal CT, 
(3-A1), PET (3-A2), and fused (3-A3) images, coronal CT (3-B1), PET (3-B2), and fused (3-B3) images, axial CT, (3-E1), PET (3-E2), and fused (3-E3) 
images, lateral (3-D1) and anterior view (3-D2) of maximum intensity projection (MIP) images. 
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restaging process could be safely based on PET imaging. The 
concordance between F18-FDG-PET/CT results and radiologic 
imaging seems to confirm PET accuracy and reliability, suggest-
ing the opportunity to use one total body study only to reduce 
doses to patients and costs. 
Conclusions
F18-FDG-PET/CT is a feasible and reliable method to re-
stage patients affected by previously histologically confirmed 
GIST, also in the absence of a staging study, in concordance 
with radiologic findings. The possibility to use a single study to 
restage patients could reduce absorbed doses, optimize clinical 
management (reducing time from relapse diagnosis to treatment), 
and reduce costs. Moreover, these studies could be safely consi- 
dered the new baseline with which to assess subsequent imatinib 
mesylate therapy efficacy.  
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